| Literature DB >> 27757926 |
Mehtab Parveen1, Faheem Ahmad2, Ali Mohammed Malla2, Shaista Azaz2, Mahboob Alam3, Omer A Basudan4, Manuela Ramos Silva5, Pedro S Pereira Silva5.
Abstract
Phytochemical investigations of the ethanolic extract of leaves of Clutia lanceolata (Family: Euphorbiaceae) resulted in the isolation of four compounds viz. 3,4-dihydroxy-2-methylbenzoic acid (1), 2,2'-dihydroxy-1,1'-binaphthyl (2), 1,3,8-trihydroxy-6-methylanthracene-9,10-dione (3) and 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one (4). Although all the isolated compounds were known but this was the first report from this plant source. Their structures were established on the basis of chemical and physical evidences viz. elemental analysis, FT-IR, 1H-NMR, 13C-NMR and mass spectral analysis. Structure of compound 2 and 4 was further authenticated by single-crystal X-ray analysis and density functional theory calculations. The isolated compounds (1-4) were screened for AChE enzyme inhibition assay in which compound 3 and 4 were found to be more potent AChE inhibitor. Molecular docking study of potent AChE inhibitor was performed to find the probable binding mode of the compounds into the active site of receptor. Moreover, the isolated compounds were also screened for in vivo cytotoxicity by brine shrimp lethality assay.Entities:
Keywords: AChE; Clutia lanceolata; Cytotoxicity; Molecular docking; X-ray crystallography
Year: 2016 PMID: 27757926 PMCID: PMC5136371 DOI: 10.1007/s13659-016-0110-x
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Fig. 1Structure of isolated compounds (1–4) from Clutia lanceolata
Fig. 2Asymmetric unit of compound 2 with the ellipsoids drawn at the 50 % probability level
Fig. 3Asymmetric unit of compound 4 with the ellipsoids drawn at the 50 % probability level
Crystal data and structure refinements of compound 2 and 4
| Compound | Compound | |
|---|---|---|
| Empirical formula | C20H14O2 | C21H20O6 |
| Formula weight | 286.31 | 368.37 |
| Temperature | 293(2) K | 293(2) K |
| Wavelength | 0.71073 Å | 0.71073 Å |
| Crystal system | Orthorhombic | Monoclinic |
| Space group |
|
|
|
| 21.5986(8) Å | 12.6851(5) Å |
|
| 15.6844(6) Å | 7.1848(3) Å |
|
| 8.6243(3) Å | 19.8951(8) Å |
|
| 90º | 90.00º |
|
| 90º | 95.223(2)º |
|
| 90º | 90.00º |
| Volume | 2921.58(19) Å3 | 1805.71(13) Å3 |
| Z | 8 | 4 |
| Density (calculated) | 1.302 gcm−3 | 1.355 gcm−3 |
| Absorption coefficient | 0.083 mm−1 | 0.099 mm−1 |
| Extinction coefficient | 0.0052(12) | – |
|
| 1200 | 776 |
| Crystal size | 0.53 × 0.48 × 0.24 mm3 | 0.60 × 0.46 × 0.44 mm3 |
| θ range for data collection | 3.11–25.84º | 1.99–29.73º |
| Index ranges | −26 < | −17 < |
| Reflections collected | 24389 | 39945 |
| Independent reflections | 2832 | 5076 |
| Completeness to 2θ = 50º | 99.8 % | 98.8 % |
| Refinement method | Full matrix LS on | Full matrix LS on |
| Data/restrains/parameters | 2832/1/206 | 5076/0/255 |
| Goodness-of-fit on | 1.104 | 1.033 |
| Final |
|
|
|
|
|
|
| Largest diff. peak and hole | 0.163 and −0.204 | 0.342 and −0.301 |
Comparison of selected geometrical parameters for compound 2 as determined by X-Ray diffraction and from the DFT geometry optimization (Å,°)
| Experimental | DFT | |
|---|---|---|
| O1–C2 | 1.375(5) | 1.358 |
| O2–C12 | 1.351(6) | 1.358 |
| C1–C11 | 1.496(5) | 1.496 |
| C1–C2 | 1.367(6) | 1.390 |
| C11–C12 | 1.388(6) | 1.390 |
| C1–C2–C3 | 122.1(4) | 121.4 |
| C11–C12–C13 | 120.4(4) | 121.3 |
| C2–C1–C11 | 120.2(4) | 118.9 |
| C1–C11–C12 | 118.8(4) | 118.9 |
| C2–C1–C11–C12 | −88.8(5) | −96.1 |
| O1–C2–C3–C4 | −180.0(4) | −180.0 |
| O2–C12–C13–C14 | −178.4(5) | −180.0 |
Comparison of selected geometrical parameters for compound 4 as determined by X-Ray diffraction and from the DFT geometry optimization (Å,°)
| Experimental | DFT | |
|---|---|---|
| O1–C2 | 1.3635(16) | 1.3553 |
| O4–C17 | 1.3583(16) | 1.3552 |
| O5–C1 | 1.3626(16) | 1.3726 |
| O6–C18 | 1.3606(18) | 1.3717 |
| O5–C23 | 1.4170(19) | 1.4227 |
| O6–C21 | 1.408(2) | 1.4237 |
| O2–C9 | 1.2982(17) | 1.2554 |
| O3–C11 | 1.2867(18) | 1.3290 |
| C8–C9 | 1.4578(17) | 1.4721 |
| C9–C10 | 1.3898(18) | 1.4403 |
| C10–C11 | 1.4052(18) | 1.3793 |
| C11–C12 | 1.4544(18) | 1.4590 |
| C1–O5–C23 | 117.42(11) | 118.51 |
| C18–O6–C21 | 118.19(12) | 118.54 |
| O5—C1–C6 | 125.72(13) | 126.21 |
| O6–C18–C19 | 125.18(13) | 126.17 |
| C8–C9–C10 | 121.39(12) | 117.09 |
| C9–C10–C11 | 120.62(12) | 120.75 |
| C10–C11–C12 | 124.30(13) | 124.77 |
| C23–O5–C1–C6 | 8.0(2) | 0.5 |
| C21–O6–C18–C19 | 5.3(2) | 2.1 |
| C6–C5–C7–C8 | −4.6(2) | 0.0 |
| C12–C13–C14–C19 | 24.7(2) | 13.9 |
Fig. 4Comparison of the molecular conformation of compound 2, as established from the X-ray study (red) with the optimized geometry (blue). (Software used for visualization: VMD, version 1.9.1, January 29, 2012 [24])
Fig. 5Comparison of the molecular conformation of compound 4, as established from the X-ray study (red) with the optimized geometry (blue). (Software used for visualization: VMD, version 1.9.1, January 29, 2012 [24])
In vitro AChE inhibition IC50 (μM) of compounds 1–4 and reference drug tacrine
| S. no. | Compounds | IC50 (µM)a ± SEM for |
|---|---|---|
| 1 | Compound | 23.7 ± 0.02 |
| 2 | Compound | 21.9 ± 0.05 |
| 3 | Compound | 14.2 ± 0.06 |
| 4 | Compound | 16.4 ± 0.03 |
| 5 | Tacrine (standard) | 0.20 ± 0.01 |
IC50 = Concentration of inhibitor required to decrease enzyme activity by 50 %
Fig. 6Interactions profile of a compound 3 and b compound 4 with receptor
Fig. 7HB plot of interacted residues in protein with compound 3 (a) and compound 4 (b)
In vivo cytotoxicity assay of isolated compounds (1–4)
| S. no. | Compound | LD50 value (μg/mL) |
|---|---|---|
| 1 | Compound | 23.40 ± 0.02 |
| 2 | Compound | 17.78 ± 0.05 |
| 3 | Compound | 13.80 ± 0.03 |
| 4 | Compound | 11.66 ± 0.04 |
| 5 | Vincristine sulphate (Standard) | 8.84 ± 0.01 |